The Role of Theranostics in Prostate Cancer
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Seminars in Radiation Oncology
- Vol. 31 (1) , 71-82
Abstract
No abstract availableKeywords
This publication has 102 references indexed in Scilit:
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate CancerClinical Cancer Research, 2009
- Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate CancerJournal of Clinical Oncology, 2009
- Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2009
- Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directionsNature Clinical Practice Oncology, 2007
- Competitive inhibition of a glutamate carboxypeptidase by phosphonamidothionate derivatives of glutamic acidBioorganic & Medicinal Chemistry Letters, 1999